eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | hyperthermia |
| Comorbidity | C1140680|ovarian ca |
| Sentences | 6 |
| PubMedID- 20878160 | Txt 75–100 mg/m2 every 3–4 weeks is associated with a quite pronounced neutropenia, with an up to 44% rate of febrile neutropenia in patients with recurrent ovarian cancer [17]. |
| PubMedID- 24675243 | Aim: the present study reports our experience concerning with the advanced cancer treatment (cytoreductive surgery and hyperthermic intraperitoneal chemotherapy) in patients with advanced ovarian cancer ephitelial (aeos) or recurrent ovarian cancer ephitelial (reoc). |
| PubMedID- 24761216 | Clinical trials have reported that the incidence of febrile neutropenia in patients with ovarian cancer receiving paclitaxel and carboplatin (tc) chemotherapy is<10% [9,10], and the guidelines indicate that csfs are not needed for primary prophylaxis in these patients. |
| PubMedID- 24657302 | Objective: evaluate the cost-effectiveness of primary prophylaxis (pp) or secondary prophylaxis (sp) with pegfilgrastim, filgrastim (6-day and 11-day), or no prophylaxis to reduce the risk of febrile neutropenia (fn) in patients with recurrent ovarian cancer receiving docetaxel or topotecan. |
| PubMedID- 26384807 | Intraoperative hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer. |
| PubMedID- 21474115 | Background: few data exist on the treatment of peritoneal surface dissemination (psd) from ovarian cancer (oc) with hyperthermic intraperitoneal chemotherapy (hipec). |
Page: 1